Background: Topical immunotherapy with diphencyprone (DPCP) for the treatment of severe alopecia areata has been used since 1983 and is felt to be the treatment of choice for chronic extensive alopecia areata. Highly variable results have been reported. The purposes of this study were to evaluate the efficacy of DPCP in the treatment of chronic, extensive alopecia areata and to assess the long-...

Diphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions and used therapeutically for various conditions including alopecia areata melanoma metastases. Prior work has shown gene expression markers of major T cell subsets (Th1, Th2, Th17) are significantly increased at 3 days after single application DPCP in healthy volunteers. We evaluated the cutaneous proteo...

Diphencyprone (DPCP), a hapten that causes delayed-type hypersensitivity reactions, has shown up to 84% efficacy in treating cutaneous metastases melanoma patients. While transcriptomic analysis of skin biopsies from treated with topical DPCP revealed increases Th1-related genes, serum proteomic these patients not yet been done. We evaluated the proteome five twice weekly until day 112, assessi...

Diphencyprone (DPCP) is a hapten that causes delayed-type hypersensitivity (DTH) reactions in human skin, and is used as a topical therapeutic for alopecia areata, warts, and cutaneous melanoma metastases. We examined peak DTH reactions induced by DPCP (3 days post-challenge) by comprehensive gene expression and histological analysis. To better understand how these DTH reactions naturally resol...

Diphencyprone (DPCP) is a hapten that causes delayed-type hypersensitivity (DTH) reactions in human skin, and is used as a topical therapeutic for alopecia areata, warts, and cutaneous melanoma metastases.  We examined peak DTH reactions induced by DPCP (3 days post-challenge) by comprehensive gene expression and histological analysis.  To better understand how these DTH reactions naturally res...

Background: Highly variable results of topical immunotherapy with Diphencyprone (DPC) in the treatment of Alopecia areata have been reported so far. Objective: The purpose of this study was to evaluate the efficacy and tolerability of DPC in the treatment of severe and chronic chronic Alopecia areata. Patients and Methods: 28 patients (16 female and 12 male, 10-35 years old, mean age 25 years) ...